Defeating Alzheimer's disease and other dementias: a priority for European science and society
Executive summary Alzheimer's disease (AD) is the leading cause of dementia, and
because the primary risk factor for AD is old age, the prevalence of the disease is increasing …
because the primary risk factor for AD is old age, the prevalence of the disease is increasing …
Tip of the iceberg: assessing the global socioeconomic costs of Alzheimer's disease and related dementias and strategic implications for stakeholders
YH El-Hayek, RE Wiley, CP Khoury… - Journal of …, 2019 - content.iospress.com
While it is generally understood that Alzheimer's disease (AD) and related dementias
(ADRD) is one of the costliest diseases to society, there is widespread concern that …
(ADRD) is one of the costliest diseases to society, there is widespread concern that …
Global status report on the public health response to dementia
World Health Organization - 2021 - digitalcommons.fiu.edu
The increasing global prevalence of dementia and consequent social and economic impacts
on people living with dementia and their families pose significant challenges for societies …
on people living with dementia and their families pose significant challenges for societies …
The cost of Alzheimer's disease in China and re‐estimation of costs worldwide
Introduction The socioeconomic costs of Alzheimer's disease (AD) in China and its impact
on global economic burden remain uncertain. Methods We collected data from 3098 …
on global economic burden remain uncertain. Methods We collected data from 3098 …
The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on …
The National Institute on Aging and the Alzheimer's Association charged a workgroup with
the task of develo** criteria for the symptomatic predementia phase of Alzheimer's …
the task of develo** criteria for the symptomatic predementia phase of Alzheimer's …
Cost of disorders of the brain in Europe 2010
BACKGROUND: The spectrum of disorders of the brain is large, covering hundreds of
disorders that are listed in either the mental or neurological disorder chapters of the …
disorders that are listed in either the mental or neurological disorder chapters of the …
Cost-effectiveness of aducanumab and donanemab for early Alzheimer disease in the US
Importance Several anti–amyloid monoclonal antibodies have been developed for slowing
the progression of Alzheimer disease (AD). Among the furthest developed are aducanumab …
the progression of Alzheimer disease (AD). Among the furthest developed are aducanumab …
Epidemiological and economic burden of Alzheimer's disease: a systematic literature review of data across Europe and the United States of America
C Takizawa, PL Thompson… - Journal of …, 2014 - journals.sagepub.com
Background: Alzheimer's disease (AD) weighs heavily on health expenditure and is strongly
associated with increasing age. Due to population aging, increasing global prevalence of …
associated with increasing age. Due to population aging, increasing global prevalence of …
The costs of dementia in Europe: an updated review and meta-analysis
Abstract Background and Objective The prevalence of dementia is increasing, while new
opportunities for diagnosing, treating and possibly preventing Alzheimer's disease and other …
opportunities for diagnosing, treating and possibly preventing Alzheimer's disease and other …
Interventions to delay functional decline in people with dementia: a systematic review of systematic reviews
Objective To summarise existing systematic reviews that assess the effects of non-
pharmacological, pharmacological and alternative therapies on activities of daily living …
pharmacological, pharmacological and alternative therapies on activities of daily living …